Long-term disease stabilization in a patient with relapsed neuroblastoma after allogeneic hematopoietic stem cell transplantation. Clinical case and literature review

Neuroblastoma (NB) is a malignant pediatric tumor originating from undifferentiated neural crest cells. About 20 % of high-risk group patients are high-risk group patients are refractory to first line therapy and about 50 % of initial responders later develop a relapse. There is no common tactics for salvage therapy. In spite of a c relatively high response rate observed for most second- and third-line therapy regimens used, the long-term event-free survival is still as low as 5 %, which implies a need for consolidation, e.g. by allogeneic hematopoietic stem cell transplantation (allo-HSCT) from haploidentical donor. 

We present a case report of a patient with systemic NB relapse achieving a long-term disease stabilization after a haplo-HSCT and post-transplant therapy. 

1. Ward E., DeSantis C., Robbins A., Kohler B., Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014;64(2):83–103. doi: 10.3322/caac.21219.

2. Berthold F., Spix C., Kaatsch P., Lampert F. Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979–2015. Paediatr Drugs 2017;19(6):577–93. doi: 10.1007/s40272- 017-0251-3.

3. Cohn S., Pearson A., London W. et al.; INRG Task Force. The International Neuroblastoma Risk Group (INRG) classification system: and INRG Task Force report. J Clin Oncol 2009;27(2):289–97. doi: 10.1200/JCO.2008.16.6785.

4. Park J., Bagatell R., Cohn S. et al. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2017;35(22):2580–7. doi: 10.1200/JCO.2016.72.0177.

5. Marachelian A., Villablanca J., Liu C. et al. Expression of five neuroblastoma genes in bone marrow or blood of patients with relapsed/refractory neuroblastoma provides a new biomarker for disease and progression. Clin Cancer Res 2017;23(18):5374–83. doi: 10.1158/1078-0432.CCR-16-2647.

6. Tadeo I., Berbegall A., Castel V. et al. Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort. Br J Cancer 2016;115(4):480–9. doi: 10.1038/bjc.2016.210.

7. London W., Castel V., Monclair T. et al. Clinical and biological features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group Project. J Clin Oncol 2011;29(24):3286–92. doi: 10.1200/JCO.2010.34.3392.

8. Simon T., Berthold F., Borkhardt A. et al. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer 2011;56(4):578–83. doi: 10.1002/pbc.22693.

9. Basta N., Halliday G., Makin G. et al. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer 2016;115(9):1048–57. doi: 10.1038/bjc.2016.302.

10. London W., Bagatell R., Weigel B. et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials. Cancer 2017;123(24):4914–23. doi: 10.1002/cncr.30934.

11. Moreno L., Rubie H., Varo A. et al. Outcome of children with relapsed or refractory neuroblastoma: a meta-analysis of ITCC/SIOPEN European phase II clinical trials. Pediatr Blood Cancer 2017;64(1):25–31. doi: 10.1002/pbc.26192.

12. Wolfl M., Jungbluth A., Garrido F. et al. Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother 2005;54(4):400–6. doi: 10.1007/s00262-004- 0603-z.

13. Ladenstein R., Potschger U., Hartman O. et al.; EBMT Paediatric Working Party. 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transplant 2008;41 Suppl 2:S118–27. doi: 10.1038/bmt.2008.69.

14. Hale G., Arora M., Ahn K. et al. Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience. Bone Marrow Transplant 2013;48(8):1056– 64. doi: 10.1038/bmt.2012.284.

15. Sivori S., Parolini S., Marcenaro E. et al. Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines. J neuroimmunol 2000;107(2):220–25. PMID: 10854660.

16. Perez-Martinez A., de Prada Vicente I., Fernandez L. et al. Natural killer cells can exert a graft-cs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors. Exp Hematol 2012;40(11):882–91.e1. doi: 10.1016/j.exphem.2012.07.004.

17. Venstrom J., Zheng J., Noor N. et al. KIR and HLA genotypes are associated with disease progression and survival following autologous hemopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res 2009;15(23):7330–4. doi: 10.1158/1078-0432.CCR-09-1720.

18. Erbe A., Wang W., Carmichael L. et al. Neuroblastoma patients’ KIR and KIR-ligand genotypes influence clinical outcome for dinutuximab-based immunotherapy: a report from the Children’s Oncology Group. Clin Cancer Res 2018;24(1):189–96. doi: 10.1158/1078-0432.CCR-17-1767.

19. Neal Z., Imboden M., Rakhmelevich A. et al. NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy. Cancer Immunol Immunother 2004;53(1):41–52. doi: 10.1007/s00262-003- 0435-2.

20. Lang P., Toporskj J., Handgretinger R. et al. Haploidentical stem cell transplantation in children with relapsed neuroblastoma. Bone Marrow Transplant 2009;43(S1):S42. doi: 10.1007/s00262-003-0435-2.

21. Lang P., Illhardt T., Ebinger M. et al. Haploidentical stem cell transplantation and subsequent immunotherapy with antiGD2 antibody for patients with relapsed metastatic neuroblastoma. J Clin Oncol 2015;33(Suppl; abstr. 10056). doi: 10.1007/s00262-003-0435-2.

22. Kanold J., Paillard C., Tchirkov A. et al. NK cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT. Pediatr Blood Cancer 2012;59(4):739–42. doi: 10.1002/pbc.24030.

23. Suzuki M., Kushner B., Kramer K. et al. Anti-GD2 immunotherapy in adults with high-risk neuroblastoma (HR-NB): The Memorial Sloan Kettering Cancer Center (MSKCC) experience. J Clin Oncol 2017;35(15s): abstr. 10550. doi: 10.1007/s00262-003-0435-2.

24. Marachelian A., Shimada H., Sano H. et al. The signifiance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma. Pediatr Blood Cancer 2012;58(5):675–81. PMID: 22493777.

25. Okamoto Y., Kodama Y., Nishikawa T. et al. Persistent positive metaiodobenzyl-guanidine scans after autologous peripheral blood stem cell transplantation may indicate maturation of stage 4 neuroblastoma. Pediatr Hematol Oncol 2017;34(3):157–64. doi: 10.1080/08880018.2017.1348414.

26. Carpentieri A., Cozzoli E., Scimeca M. et al. Differentiation of human neuroblas toma cells toward the osteogenic lineage by mTOR inhibitor. Cell Death Dis 2015;6:e1974. doi: 10.1038/cddis.2015.244.